0

Explore original, structured summaries for research and education.

Research profile

Tirzepatide(Mounjaro)

(Mounjaro)

Tirzepatide(Mounjaro) is indexed as a Dual GLP-1/GIP agonist research entry. Its current evidence category is (Mounjaro), and published discussion commonly places it within Weight Loss, Metabolic. This profile summarizes identifiers and literature signals; it does not provide treatment or dosing advice.

Weight LossMetabolic

Identity

Molecular Data

Molecular weight
4,813.55 Da
Chain length
39 amino acids
Type
Dual GLP-1/GIP agonist
Reported half-life
~5 days (120 hours)
Amino-acid sequenceHis-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-Gly-Gly-Gly-Gly-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys

Literature map

Research indications

Weight Loss

  • Severe Obesity Managementmost effective
  • Metabolic Syndrome Reversalmost effective
  • Body Composition Optimizationeffective

Diabetes

  • Type 2 Diabetes Managementmost effective
  • Insulin Resistance Improvementeffective
  • Beta Cell Preservationeffective

Cardiovascular

  • MACE Reductioneffective
  • Blood Pressure Reductioneffective
  • Lipid Profile Improvementmoderate

Evidence-gated guidance

Dosing Protocols

Current U.S. Mounjaro prescribing-label summary for type 2 diabetes. This is not individualized medical advice; indication, age, comorbidities, and concurrent medicines must be reviewed by a licensed prescriber.

Dose
2.5 mg once weekly for 4 weeks, then 5 mg once weekly; if needed, increase by 2.5 mg only after at least 4 weeks at the current dose. Adult maximum: 15 mg weekly.
Frequency
Once weekly, on the same day each week, with or without meals.
Cycle
Ongoing prescription therapy only while the prescriber judges benefit, tolerability, and indication appropriate.
Storage
Keep refrigerated at 2–8°C in the original carton and protect from light. Do not freeze. May be kept at up to 30°C for a total of 21 days, then discard.
Open peptide calculator →Read the official prescribing label ↗

Combination risks

Interactions

Insulin and insulin secretagogues

Concomitant use can increase hypoglycemia risk; the prescriber may need to adjust those medicines and monitor glucose.

Oral medicines

Delayed gastric emptying can affect absorption of oral medicines, especially those requiring threshold concentrations or close monitoring.

Oral contraceptives

The label advises a non-oral method or added barrier method for 4 weeks after initiation and for 4 weeks after each dose increase.

Procedures and anesthesia

Tell the care team before planned surgery or deep sedation because delayed gastric emptying may raise aspiration risk.

Evidence-informed overview

What to Expect

Dose escalation

The starting dose is for treatment initiation; escalation is gradual to improve tolerability. Do not accelerate the schedule.

Monitoring

Clinicians monitor glycemic response, gastrointestinal tolerability, hydration, hypoglycemia risk with other diabetes medicines, and relevant complications.

Individual response

Appetite, glucose, weight, and adverse-effect responses vary. Trial averages do not predict an individual result.

Risk overview

Side Effects & Safety

Mounjaro carries a boxed warning for thyroid C-cell tumors observed in rats; human relevance is unknown. It is contraindicated with a personal or family history of medullary thyroid carcinoma, MEN 2, or serious hypersensitivity to tirzepatide.

Common or expected reactions

  • Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain are the most commonly reported reactions.

Seek medical advice promptly

  • Seek prompt medical advice for severe or persistent abdominal pain, serious allergic symptoms, persistent vomiting/dehydration, gallbladder symptoms, or severe hypoglycemia.

Contraindications

  • Personal or family history of medullary thyroid carcinoma; MEN 2; known serious hypersensitivity to tirzepatide or product excipients.

Verification

Quality Checklist

  1. Use only a lawfully supplied, prescription product from an authorized pharmacy.
  2. Verify product name, strength, lot, expiry, intact packaging, and required Medication Guide.
  3. Maintain the labeled cold chain, protect from light, never freeze, and discard after the allowed room-temperature period.
  4. Do not treat unlabeled or research-grade tirzepatide as equivalent to an approved product.

Clear answers

Frequently Asked Questions

What is the labeled starting dose?

For Mounjaro, the U.S. label starts at 2.5 mg once weekly for 4 weeks, then increases to 5 mg once weekly. Further increases require at least 4 weeks at the current dose and prescriber review.

Is Mounjaro the same indication as Zepbound?

They contain tirzepatide but have different brand labeling and approved indications. This dosing summary follows the Mounjaro diabetes label; use the label for the product actually prescribed.

Can the dose be increased faster?

The label requires at least 4 weeks at the current dose before a 2.5 mg increase. Do not accelerate titration without the prescriber.

Does the calculator replace a prescription?

No. The calculator is an arithmetic aid and does not select a dose, verify a product, or replace the prescriber or product label.

Source trail

References

  1. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)Jastreboff, A.M., et al. · New England Journal of Medicine · 2022
  2. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)Frías, J.P., et al. · New England Journal of Medicine · 2021
  3. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)Garvey, W.T., et al. · The Lancet · 2023
  4. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT)Nicholls, S.J., et al. · New England Journal of Medicine · 2025
  5. Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 3-Year Extension)Jastreboff, A.M., et al. · New England Journal of Medicine · 2025
  6. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT)Packer, M., et al. · New England Journal of Medicine · 2024
  7. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)Aronne, L.J., et al. · New England Journal of Medicine · 2025
  8. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA)Malhotra, A., et al. · New England Journal of Medicine · 2024

View the structural source profile ↗